LunarCrush LLM | creator/twitter::1014974088618659840/posts

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@AM231982](/creator/twitter/AM231982)
"We already know Avacta have cracked the half-life limitation and increased it to over 60+ hours (note the comment on the next page referencing a typical X hours They have also increased the therapeutic index window by 75X. We are not done yet.They dosed 50mg/kg with 'NO TOXICITY NOTED' If this doesn't wipe the floor with Pharma's best efforts on Exatecan derivatives I will be astounded. Think Nokia 6310 to latest iPhone and you get to miss out everything in between. It is that significant. (3/5)"  
[X Link](https://x.com/AM231982/status/1975852731551125831) [@AM231982](/creator/x/AM231982) 2025-10-08T09:16Z XXX followers, XXX engagements


"Daiichi Sankyo dosed over 1000 patients with Exatecan in clinical trials but ultimately it failed in the clinic. Today they use Deruxtecan (basically a watered down version of Exatecan) in their blockbuster ADC drug Enhertu Enhertu is expected to generate $11.2bn by 2030 per year. Imagine what AVA6103 could do with a much wider total addressable market (TAM) vs Enhertu which is limited by HER2 expression. Avacta's PreCISION uses FAP which is fortunately present in XX% of solid tumours (4/5)"  
[X Link](https://x.com/AM231982/status/1975852734940131810) [@AM231982](/creator/x/AM231982) 2025-10-08T09:16Z XXX followers, XXX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@AM231982 "We already know Avacta have cracked the half-life limitation and increased it to over 60+ hours (note the comment on the next page referencing a typical X hours They have also increased the therapeutic index window by 75X. We are not done yet.They dosed 50mg/kg with 'NO TOXICITY NOTED' If this doesn't wipe the floor with Pharma's best efforts on Exatecan derivatives I will be astounded. Think Nokia 6310 to latest iPhone and you get to miss out everything in between. It is that significant. (3/5)"
X Link @AM231982 2025-10-08T09:16Z XXX followers, XXX engagements

"Daiichi Sankyo dosed over 1000 patients with Exatecan in clinical trials but ultimately it failed in the clinic. Today they use Deruxtecan (basically a watered down version of Exatecan) in their blockbuster ADC drug Enhertu Enhertu is expected to generate $11.2bn by 2030 per year. Imagine what AVA6103 could do with a much wider total addressable market (TAM) vs Enhertu which is limited by HER2 expression. Avacta's PreCISION uses FAP which is fortunately present in XX% of solid tumours (4/5)"
X Link @AM231982 2025-10-08T09:16Z XXX followers, XXX engagements